Rhythm Biosciences Provides Quarterly Update
Key points
- Genetype secures two strategic distribution partnerships
- Clinical study with University of Melbourne reaches 90%+ milestone
- Strategic agreement with Memorial Sloan Kettering Cancer Center
- ColoSTAT® achieves breakthrough clinical performance
Full summary
Rhythm Biosciences Ltd (ASX:RHY), a transformative cancer diagnostics company, has released its business update and Appendix 4C for Q1 FY26. Key highlights include Genetype securing two strategic distribution partnerships, the clinical study with the University of Melbourne reaching a 90%+ milestone, a strategic agreement with Memorial Sloan Kettering Cancer Center, and ColoSTAT® achieving breakthrough clinical performance across all stages of colorectal cancer. The company also successfully raised $3.75m through an oversubscribed placement. Rhythm's CEO, Dr. David Atkins, commented that the strong start to FY26 positions the company to deliver on its strategic objectives for the year ahead. The company remains confident that FY26 will be a transformative year as it continues to execute its growth strategy and outperform internal expectations.
Guidance
Rhythm Biosciences expects FY26 revenue performance of Genetype to be well aligned to internal assumptions, on track to deliver significant quarter-on-quarter growth milestones.
Summary generated by a large language model. Please interpret with care.